[{"address1": "22 Boston Wharf Road", "address2": "Floor 7", "city": "Boston", "state": "MA", "zip": "02210", "country": "United States", "phone": "929 274 7510", "fax": "929 274 7553", "website": "https://www.akaritx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 6, "companyOfficers": [{"maxAge": 1, "name": "Dr. Samir Rashmikant Patel M.D.", "age": 54, "title": "Interim President, CEO & Director", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 3704, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Wendy F. DiCicco CPA", "age": 56, "title": "Interim Chief Financial Officer", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 540343, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Miles  Nunn", "age": 54, "title": "Chief Scientific Officer", "yearBorn": 1969, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.79, "open": 3.82, "dayLow": 3.2481, "dayHigh": 3.82, "regularMarketPreviousClose": 3.79, "regularMarketOpen": 3.82, "regularMarketDayLow": 3.2481, "regularMarketDayHigh": 3.82, "beta": 0.948, "forwardPE": -0.9553235, "volume": 9981, "regularMarketVolume": 9981, "averageVolume": 22850, "averageVolume10days": 16010, "averageDailyVolume10Day": 16010, "marketCap": 38825840, "fiftyTwoWeekLow": 1.078, "fiftyTwoWeekHigh": 4.4, "fiftyDayAverage": 3.5226, "twoHundredDayAverage": 2.60135, "currency": "USD", "enterpriseValue": 87496073216, "floatShares": 12750027908, "sharesOutstanding": 11953400, "sharesShort": 29178, "sharesShortPriorMonth": 24929, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0023999999, "heldPercentInsiders": 0.38214, "heldPercentInstitutions": 0.01559, "shortRatio": 1.77, "shortPercentOfFloat": 0.0032, "impliedSharesOutstanding": 5061160, "bookValue": -0.305, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -20133000, "trailingEps": -2.99, "forwardEps": -3.4, "lastSplitFactor": "1:20", "lastSplitDate": 1692230400, "enterpriseToEbitda": -4838.85, "52WeekChange": 0.008264422, "SandP52WeekChange": 0.24014747, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "AKTX", "underlyingSymbol": "AKTX", "shortName": "Akari Therapeutics Plc", "longName": "Akari Therapeutics, Plc", "firstTradeDateEpochUtc": 1389018600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "7ad3d9ad-13c2-3784-92d6-18475fbe0a3b", "messageBoardId": "finmb_306632341", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.2481, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 4177000, "ebitda": -18082000, "totalDebt": 1000000, "quickRatio": 0.476, "currentRatio": 0.578, "returnOnAssets": -1.7282699, "freeCashflow": -7512510, "operatingCashflow": -15796000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]